- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Curasight to present at HC Andersen Capital | 1 | Cision News | ||
| Do | CURASIGHT: Interim report Q3 2025 | 2 | Cision News | ||
| 26.11. | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 192 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen | |
| 13.11. | Curasight to present at Dansk Aktionærforening InvestorDagen | 3 | Cision News | ||
| 29.10. | Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting | 4 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 01.10. | Curasight announces broadening and extension of patent protection for uTRACE | 1 | Cision News | ||
| 03.09. | Transaction with shares in Curasight A/S made by managerial employee | 1 | Cision News | ||
| 28.08. | CURASIGHT: Half-year report Q2 2025 | 1 | Cision News | ||
| 26.08. | Curasight receives approval for brain cancer treatment trial | 1 | Investing.com | ||
| 26.08. | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 251 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen | |
| 23.06. | Curasight A/S announces outcome of T03 warrant exercise | 2 | Cision News | ||
| 18.06. | Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT in brain cancer patients | 1 | Cision News | ||
| 13.06. | Spotlight Stock Market: Market Notice 110/25 - Last day of trading in Curasight A/S's subscription option CURAS TO 3 | 1 | Cision News | ||
| 19.03. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 19.03.2025 | 181 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 19.03.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 19.03.2025ISIN NameDK0061295797 CURASIGHT A/S DK -... ► Artikel lesen | |
| 31.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 31.01.2025 | 1.205 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.01.2025
Aktien
1 CA6699882065 Nu E Power Corp.
2... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,54 | +0,27 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| POLYRIZON | 7,330 | 0,00 % | Polyrizon Ltd.: Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform | Ra'anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,250 | +12,67 % | Why Vera Therapeutics Stock Rocked the Market on Tuesday | ||
| COGENT BIOSCIENCES | 38,980 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| JANUX THERAPEUTICS | 15,820 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOVANT | 22,020 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,150 | -3,90 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 40,405 | -1,42 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NUVALENT | 104,96 | -1,37 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,430 | -3,10 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| KYMERA THERAPEUTICS | 64,27 | -3,87 % | Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? | ||
| APOGEE THERAPEUTICS | 69,13 | +0,41 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,010 | +1,44 % | Harmony Biosciences to present Dravet syndrome trial data at AES meeting | ||
| DISC MEDICINE | 89,72 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 178,96 | -3,03 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
CURASIGHT A/S gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,000 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.